Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Payables (2016 - 2025)

Historic Payables for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $92.3 million.

  • Integra Lifesciences Holdings' Payables rose 1884.87% to $92.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.3 million, marking a year-over-year increase of 1884.87%. This contributed to the annual value of $82.5 million for FY2024, which is 1064.06% down from last year.
  • According to the latest figures from Q3 2025, Integra Lifesciences Holdings' Payables is $92.3 million, which was up 1884.87% from $92.8 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' Payables' 5-year high stood at $112.8 million during Q1 2023, with a 5-year trough of $59.6 million in Q3 2021.
  • In the last 5 years, Integra Lifesciences Holdings' Payables had a median value of $91.3 million in 2025 and averaged $85.6 million.
  • In the last 5 years, Integra Lifesciences Holdings' Payables crashed by 3663.78% in 2021 and then soared by 6511.15% in 2022.
  • Over the past 5 years, Integra Lifesciences Holdings' Payables (Quarter) stood at $61.8 million in 2021, then soared by 65.11% to $102.1 million in 2022, then fell by 9.57% to $92.3 million in 2023, then fell by 10.64% to $82.5 million in 2024, then grew by 11.88% to $92.3 million in 2025.
  • Its last three reported values are $92.3 million in Q3 2025, $92.8 million for Q2 2025, and $91.3 million during Q1 2025.